Phasing out the use of animals in science
Barney Reed, Senior Scientific Manager, Animals in Science Department at the RSPCA, stresses the need for ambitious strategies for phasing out the use of animals in science.
Lack of access to treatment for opioid dependence is concerning
Monica Racoviță, Senior Researcher at The Health Policy Partnership, argues that opioid dependence is a pressing issue, yet treatment for it is still out of reach for many.
The Psychedelic Renaissance: Exploring shifting attitudes towards psychedelic therapy
In a surprising turn of events, Prince Harry's public endorsement of the transformative power of psychedelic therapy has triggered a psychedelic resurgence in the UK.
Your CBD routine: What is the best time time to take CBD?
Savage Cabbage discusses the perfect CBD routine designed by you.
Cannabis for cancer: Improving sleep and pain tolerance
Could cannabis for cancer become a reality in patient wards? Researchers find the plant can improve sleep, pain, and brain clarity, easing 'chemo brain'.
Why does cannabis give us the “munchies”? Tests on worms could give clues
Researchers looking to see if giving worms cannabinoids alters their existing food preferences find that worms get the “munchies” too.
Why do the effects of an anti-ageing drug differ with gender?
The effect of the anti-ageing drug rapamycin differs in male and female fruit flies, find researchers, who seek to understand how sex influences the development of age-related disease.
Gender gaps in drug trials harm women’s health through overmedication
When conducting drug trials, it is vital to include women and men in research to prevent gender gap issues like adverse drug reactions.
What is the ‘entourage effect’ of cannabis and how can it relieve pain?
The ‘entourage effect’ of cannabis comes from the pain-relieving effects of the plant, but could we boost this pain-relieving efficacy of THC without the psychoactive side effects?
Why Europe needs to catch up with psychedelic research
David Nutt FMedSci, Chair Drug Science and PAREA, Prof of Neuropsychopharmacology at Imperial College London, explains why Europe needs to catch up with psychedelic research.
How clarity and standards can help the CBD Industry to thrive
Michael Sassano, CEO at SOMAÍ Pharmaceuticals, walks us through how clarity and standards can help the CBD Industry to thrive.
Drug combination for children with MYC amplified Medulloblastoma
Researchers discover drug combination that could offer a better prognosis for children diagnosed with MYC amplified Medulloblastoma, an often deadly form of brain cancer.
Hemp & CBD – A legitimate industry framework
Here, Savage Cabbage Ltd argue for a legitimate Industry Framework when it comes to hemp & CBD
Increasing blood-brain barrier permeability with Acoustic Cluster Therapy (ACT®) to enhance drug delivery in...
Despite the rising incidence of Central Nervous System diseases worldwide, efficient treatment options for neurological disorders remain scarce. Treatment failures are principally associated with the inability of drugs to pass the highly selective Blood-Brain Barrier rather than a lack of efficacy.
The UK CBD Market: Cannabinoids, Consumers and Confusion
Savage Cabbage Ltd give insight into the UK CBD market, defining the differences in cannabinoid products and their roles in the industry.
What can the UK Government do for access to cannabis and CBD Reform
Pointing to advancements in public health, the UK government can improve access to cannabis by altering its CBD reform.
How cannabis tracking technology can help global supply chain struggles
Lewis Koski, Chief Strategy Officer of Metrc, charts how cannabis tracking technology can help global supply chain struggles.
Germany becomes one of the first European countries to legalise cannabis
Germany has made plans to legalise cannabis, which could create up to 27,000 new jobs and save around about 4.7 billion euros.
Do you really need to be taking paracetamol?
Paracetamol is Britain’s most trusted painkiller with the average person taking up to 70 paracetamol per year, however there are safety issues.
A blueprint for the UK Cannabis Industry
Senior Associate David Hardstaff and Partner John Binns of BCL Solicitors LLP, share their views on a blueprint for the UK Cannabis Industry.